A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

Despite recent ASCO and FDA guidance recommending the inclusion of people living with HIV in pivotal cancer trials, nearly 75 ...

The U.S. Food and Drug Administration (FDA) approved a new, twice-yearly shot — the first and only of its kind — to prevent ...

Gilead’s Yeztugo will offer an alternative to treatments such as daily pills and every-other-month injections.

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to HIV-prevention infrastructure in the U.S.

June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections.

Yeztugo, a twice-a-year antiviral shot to prevent HIV, was approved by the Food and Drug Administration on Wednesday, marking ...

The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...

A newly approved HIV medication provides near-total protection against infection with just two injections a year. It's called Lenacapavir. But the high price of the drug could limit its reach.